Company: LNAI
Filing Date: 2025-02-19
Form Type: 10-Q/A
Source: 0001731122-25-000250
Chunk: 1

Company: Lunai Bioworks Inc.
Filing Date: 2025-02-19
Form: 10-Q/A
Chunk 1
---
�
No ☐

Indicate by check mark whether the registrant is a
large accelerated filer, an accelerated filer, a non-accelerated filer, or an emerging growth company. See definitions of “large
accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company”
in Rule 12b-2 of the Exchange Act.

| Large accelerated filer | ☐ | Accelerated filer         | ☐ |
| Non-accelerated filer   | ☒ | Smaller reporting company | ☒ |
|                         |   | Emerging growth company   | ☐ |

If an emerging growth company, indicate by check mark
if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a
shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐
No ☒

As of May 10, 2024, the number of shares of the registrant’s
Common Stock outstanding was 147,504,944.

<div align='center'>EXPLANATORY NOTE</div>

Renovaro Inc. (the “Company”, “we”, “our”, or
“us”) is filing this Amendment No. 2 to its Quarterly Report on Form 10-Q/A (this “Amendment”) to amend its Quarterly
Report on Form 10-Q for the quarter ended March 31, 2024, as filed with the Securities and Exchange Commission (the “SEC”)
on May 15, 2024, as amended by that Form 10-Q/A filed with the SEC on August 20, 2024, (the “Q3 2024 Form 10-Q”) to (i) restate
its financial statements as of and for the periods ended March 31, 2024, which should no longer be relied on and are being restated herein;
and (ii) describe the restatement and its impact on previously reported amounts.

We are filing this Amendment to amend and restate the Q3 2024 Form 10-Q with
modifications as necessary to reflect these restatements.

Background of Restatement

On February 18, 2025, the Audit Committee (the “Audit Committee”) of the Board of Directors